Subscribe
shutterstock_1155156751_atmosphere1
Atmosphere1 / Shutterstock.com
20 October 2020Big PharmaSarah Morgan

MSD secures victory before English court

The English High Court has concluded that Merck Sharp Dohme (MSD) is not infringing a patent owned by Pfizer through the sale of its pneumococcal conjugate vaccine.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
Australian court issues mixed vaccine patent ruling
15 October 2020   In a mixed decision for Merck Sharp Dohme, the Federal Court of Australia has concluded that the pharmaceutical company is infringing one patent owned by Wyeth, but that two other Wyeth patents are invalid.
Americas
Appeals court sides with Pfizer, Merck KGaA in $5bn suit
29 September 2020   The US Court of Appeals for the Federal Circuit has sided with EMD Serono and Pfizer over the invalidation of a multiple sclerosis drug patent, in a defeat for biotech company Biogen.
Asia-Pacific
Wyeth secures Australian injunction against MSD vaccine
30 November 2020   The Federal Court of Australia has granted Pfizer subsidiary Wyeth’s bid for an injunction against Merck Sharp Dohme in a dispute over vaccine patents.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Asia-Pacific
Australian court issues mixed vaccine patent ruling
15 October 2020   In a mixed decision for Merck Sharp Dohme, the Federal Court of Australia has concluded that the pharmaceutical company is infringing one patent owned by Wyeth, but that two other Wyeth patents are invalid.
Americas
Appeals court sides with Pfizer, Merck KGaA in $5bn suit
29 September 2020   The US Court of Appeals for the Federal Circuit has sided with EMD Serono and Pfizer over the invalidation of a multiple sclerosis drug patent, in a defeat for biotech company Biogen.
Asia-Pacific
Wyeth secures Australian injunction against MSD vaccine
30 November 2020   The Federal Court of Australia has granted Pfizer subsidiary Wyeth’s bid for an injunction against Merck Sharp Dohme in a dispute over vaccine patents.

More on this story

Asia-Pacific
Australian court issues mixed vaccine patent ruling
15 October 2020   In a mixed decision for Merck Sharp Dohme, the Federal Court of Australia has concluded that the pharmaceutical company is infringing one patent owned by Wyeth, but that two other Wyeth patents are invalid.
Americas
Appeals court sides with Pfizer, Merck KGaA in $5bn suit
29 September 2020   The US Court of Appeals for the Federal Circuit has sided with EMD Serono and Pfizer over the invalidation of a multiple sclerosis drug patent, in a defeat for biotech company Biogen.
Asia-Pacific
Wyeth secures Australian injunction against MSD vaccine
30 November 2020   The Federal Court of Australia has granted Pfizer subsidiary Wyeth’s bid for an injunction against Merck Sharp Dohme in a dispute over vaccine patents.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York